These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 17286767)

  • 41. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ; Fenske TS; Blinder MA
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhibitor development and management in three non-severe haemophilia A patients with T295A variant.
    Ivaskevicius V; Goldmann G; Horneff S; Marquardt N; Klein C; Albert T; Zeitler H; Oldenburg J
    Hamostaseologie; 2014; 34 Suppl 1():S9-12. PubMed ID: 25382774
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations.
    Boekhorst J; Lari GR; D'Oiron R; Costa JM; Nováková IR; Ala FA; Lavergne JM; VAN Heerde WL
    Haemophilia; 2008 Jul; 14(4):729-35. PubMed ID: 18503540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Incidence of inhibitors in haemophiliacs. A review of the literature.
    Scharrer I; Neutzling O
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):753-8. PubMed ID: 8292725
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age.
    Lorenzo JI; López A; Altisent C; Aznar JA
    Br J Haematol; 2001 Jun; 113(3):600-3. PubMed ID: 11380444
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhibitor development and successful immune tolerance in an HIV-infected patient with haemophilia A and after immune reconstitution with HAART.
    Kruse-Jarres R; Hadi CM; Leissinger CA
    Haemophilia; 2007 Nov; 13(6):707-11. PubMed ID: 17973846
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The need for previously untreated patient population studies in understanding the development of factor VIII inhibitors.
    Gomperts ED
    Haemophilia; 2006 Nov; 12(6):573-8. PubMed ID: 17083506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates.
    de Biasi R; Rocino A; Papa ML; Salerno E; Mastrullo L; De Blasi D
    Thromb Haemost; 1994 May; 71(5):544-7. PubMed ID: 8091377
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of primary and secondary prophylaxis on the clinical expression of joint damage in children with severe haemophilia A. Results of a multicenter non-concurrent cohort study.
    Schobess R; Kurnik K; Friedrichs F; Halimeh S; Krümpel A; Bidlingmaier C; Nowak-Göttl U
    Thromb Haemost; 2008 Jan; 99(1):71-6. PubMed ID: 18217137
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Longitudinal analysis of factor VIII inhibitors in a previously untreated mild haemophilia A patient with an Arg593-->Cys substitution.
    van den Brink EN; Timmermans SM; Turenhout EA; Bank CM; Fijnvandraat K; Voorberg J; Peters M
    Thromb Haemost; 1999 May; 81(5):723-6. PubMed ID: 10365744
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Understanding inhibitor development in haemophilia A: towards clinical prediction and prevention strategies.
    Coppola A; Santoro C; Tagliaferri A; Franchini M; DI Minno G
    Haemophilia; 2010 Jan; 16 Suppl 1():13-9. PubMed ID: 20059564
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Influence of factor VIII on overall coagulability and fibrinolytic potential of haemophilic plasma as measured by global assay: monitoring in haemophilia A.
    Goldenberg NA; Hathaway WE; Jacobson L; McFarland K; Manco-Johnson MJ
    Haemophilia; 2006 Nov; 12(6):605-14. PubMed ID: 17083510
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhibitor development in patients with hemophilia A after continuous infusion of FVIII concentrates.
    von Auer Ch; Oldenburg J; von Depka M; Escuriola-Ettinghausen C; Kurnik K; Lenk H; Scharrer I
    Ann N Y Acad Sci; 2005 Jun; 1051():498-505. PubMed ID: 16126990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rituximab in the treatment of alloimmune factor VIII and IX antibodies in two children with severe haemophilia.
    Mathias M; Khair K; Hann I; Liesner R
    Br J Haematol; 2004 May; 125(3):366-8. PubMed ID: 15086418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiology of inhibitors in haemophilia A.
    Kreuz W; Escuriola-Ettingshausen C; Martinez-Saguer I; Güngör T; Kornhuber B
    Vox Sang; 1996; 70 Suppl 1():2-8. PubMed ID: 8869461
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
    Astermark J
    Haemophilia; 2006 Dec; 12 Suppl 6():8-13; discussion 13-4. PubMed ID: 17123388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.
    Mariani G; Kroner B;
    Haematologica; 2001 Nov; 86(11):1186-93. PubMed ID: 11694405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.